Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Jörger M, Finn S, Cuffe S, Byrne A, Gray S. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opin Ther Targets 2016; 20:1339-1356.
Jul 11, 2016The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Jul 11, 2016Expert Opin Ther Targets 2016; 20:1339-1356
Jörger Markus, Finn Stephen P, Cuffe Sinead, Byrne Annette T, Gray Steven G
Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
Warschkow R, Gueller U, Tarantino I, Cerny T, Schmied B, Thürlimann B, Jörger M. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016; 263:1188-98.
Jun 1, 2016Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis
Jun 1, 2016Ann Surg 2016; 263:1188-98
Warschkow Rene, Gueller Ulrich, Tarantino Ignazio, Cerny Thomas, Schmied Bruno, Thürlimann Beat, Jörger Markus
A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
Warschkow R, Cerny T, Schmied B, Gueller U, Thürlimann B, Jörger M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.
May 17, 2016A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
May 17, 2016Br J Cancer 2016; 115:80-4
Warschkow Rene, Cerny Thomas, Schmied Bruno, Gueller Ulrich, Thürlimann Beat, Jörger Markus
Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology
Shao S, Guo T, Gross V, Lazarev A, Koh C, Gillessen Sommer S, Jörger M, Jochum W, Aebersold R. Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology. J Proteome Res 2016; 15:1821-9.
May 10, 2016Reproducible Tissue Homogenization and Protein Extraction for Quantitative Proteomics Using MicroPestle-Assisted Pressure-Cycling Technology
May 10, 2016J Proteome Res 2016; 15:1821-9
Shao Shiying, Guo Tiannan, Gross Vera, Lazarev Alexander, Koh Ching Chiek, Gillessen Sommer Silke, Jörger Markus, Jochum Wolfram, Aebersold Ruedi
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Neumair P, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Warschkow R, Joos L, Jörger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study - Abstrakt 169P.
Apr 15, 2016Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Apr 15, 2016European Lung Cancer Conference
Neumair P, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Warschkow Rene, Joos L, Jörger Markus
61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
Baty F, Jörger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016; 11:S81.
Apr 15, 201661PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
Apr 15, 2016J Thorac Oncol 2016; 11:S81
Baty Florent, Jörger Markus, Früh Martin, Brutsche Martin
Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review
Hager S, Ackermann C, Jörger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016; 27:975-84.
Apr 6, 2016Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review
Apr 6, 2016Ann Oncol 2016; 27:975-84
Hager S, Ackermann C J, Jörger Markus, Gillessen S, Omlin Aurelius
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
Hamzic S, Wenger N, Froehlich T, Jörger M, Aebi S, Largiader C, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016
Mar 22, 2016The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
Mar 22, 2016Pharmacogenomics J 2016
Hamzic S, Wenger N, Froehlich T K, Jörger Markus, Aebi S, Largiader C R, Amstutz U
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Crombag M, Jörger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8
Jan 2, 2016Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
Jan 2, 2016Cancers (Basel) 2016; 8
Crombag Marie-Rose B S, Jörger Markus, Thürlimann Beat, Schellens Jan H M, Beijnen Jos H, Huitema Alwin D R
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
Dec 11, 2015Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
Dec 11, 2015Haematologica 2015; 101:346-55
Driessen Christoph, Hess Dagmar, von Moos Roger, Pabst Thomas, Huitema Alwin, Sessa Christiana, Overkleeft Hermann S, Berthod Gregoire, Hawle Hanne, Xyrafas Alexandros, Berset Catherine, Hitz Felicitas, Bader Jürgen, Rosing Hilde, Jörger Markus, Kraus Marianne, Mey Ulrich J M
Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry
Shao S, Guo T, Koh C, Gillessen Sommer S, Jörger M, Jochum W, Aebersold R. Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry. Proteomics 2015; 15:3711-21.
Sep 10, 2015Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT-SWATH mass spectrometry
Sep 10, 2015Proteomics 2015; 15:3711-21
Shao Shiying, Guo Tiannan, Koh Chiek Ching, Gillessen Sommer Silke, Jörger Markus, Jochum Wolfram, Aebersold Ruedi
Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis
Marsico J, Rodriguez R, Müller J, Jörger M. Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis. J Cancer Res Ther 2015; 11:647.
Jul 1, 2015Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis
Jul 1, 2015J Cancer Res Ther 2015; 11:647
Marsico Jennifer Gibbons, Rodriguez Regulo, Müller Joachim, Jörger Markus
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Kraff S, Nieuweboer A, Mathijssen R, Baty F, de Graan A, van Schaik R, Jaehde U, Jörger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother Pharmacol 2015
Mar 12, 2015Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Mar 12, 2015Cancer Chemother Pharmacol 2015
Kraff Stefanie, Nieuweboer Annemieke J M, Mathijssen Ron H J, Baty Florent, de Graan Anne-Joy, van Schaik Ron H N, Jaehde Ulrich, Jörger Markus
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
Jörger M, van Schaik R, Becker M, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 2015
Mar 10, 2015Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
Mar 10, 2015Prostate Cancer Prostatic Dis 2015
Jörger Markus, van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen Sommer Silke, Rothermundt Christian
Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
Guo T, Jochum W, Jörger M, Gillessen Sommer S, Blum L, Collins B, Rosenberger G, Röst H, Wolski W, Gillet L, Koh C, Kouvonen P, Aebersold R. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 2015; 21:407-13.
Mar 2, 2015Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps
Mar 2, 2015Nat Med 2015; 21:407-13
Guo Tiannan, Jochum Wolfram, Jörger Markus, Gillessen Sommer Silke, Blum Lorenz C, Collins Ben C, Rosenberger George, Röst Hannes L, Wolski Witold E, Gillet Ludovic C, Koh Ching Chiek, Kouvonen Petri, Aebersold Ruedi
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
Feb 13, 2015Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Feb 13, 2015Cancer Chemother Pharmacol 2015; 75:763-72
Jörger Markus, Beijnen J H, Cerny Thomas, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P H M, Doodeman V D, Cats A, Boot H, Huitema A D R, Schellens J H M
Metabolism of the taxanes including nab-paclitaxel
Jörger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2014:1-12.
Nov 14, 2014Metabolism of the taxanes including nab-paclitaxel
Nov 14, 2014Expert Opin Drug Metab Toxicol 2014:1-12
Jörger Markus
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Froehlich T, Amstutz U, Aebi S, Jörger M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer 2014; 136:730-9.
Jun 27, 2014Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Jun 27, 2014Int J Cancer 2014; 136:730-9
Froehlich Tanja K, Amstutz Ursula, Aebi Stefan, Jörger Markus, Largiadèr Carlo R
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Jörger M, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D, Stahel R, Droege C, Früh M, Baty F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 2014; 85:306-13.
May 29, 2014Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
May 29, 2014Lung Cancer 2014; 85:306-13
Jörger Markus, Zappa F, Klingbiel D, Brauchli P, Rothschild S, Gautschi O, Pless M, Ochsenbein A, von Moos R, Betticher D C, Stahel R A, Droege C, Früh Martin, Baty Florent, Brutsche Martin
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Jörger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
Mar 11, 2014Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Mar 11, 2014Eur J Clin Pharmacol 2014; 70:719-25
Jörger Markus, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem Stefan, Thürlimann Beat, Cerny Thomas